Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 8/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 3/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2173127 | 0.91 | XDH (0.43) | XDHWNT3AGRM5P2RX3P2RX2 | |
| SCHEMBL3475703 | 0.89 | LDHA (0.42) | XDHWNT3AGRM5LDHA | |
| SCHEMBL1495528 | 0.85 | GRM2 (0.45) | XDHGRM2GRM5 | |
| SCHEMBL3476174 | 0.84 | GRM5 (0.43) | GRM5KDM5AKDM4CKDM5B | |
| SCHEMBL2171221 | 0.82 | SYK (0.44) | XDH | |
| SCHEMBL2171763 | 0.81 | XDH (0.46) | XDHGRM2 | |
| SCHEMBL3474788 | 0.81 | DHODH (0.42) | XDHGRM5LDHA | |
| SCHEMBL1495762 | 0.80 | LDHA (0.50) | P2RX3P2RX2LDHA | |
| SCHEMBL2188021 | 0.79 | XDH (0.43) | XDHWNT3A | |
| SCHEMBL2171975 | 0.79 | P2RX3 (0.48) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133122-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-09-15 | — | — | US | disclosed |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2014-10-30 | — | — | US | disclosed |
| WO-2010033168-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | IL1B, ADORA2B, AVPR1B | XDH 515/4885WNT3A 1920/4885GRM2 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.